[SCHEDULE 13G] Purple Biotech Ltd. American SEC Filing

Rhea-AI Filing Summary

Purple Biotech Ltd. received a Schedule 13G from Lincoln Alternative Strategies LLC reporting beneficial ownership of 605,000 American Depositary Shares, equal to 9.94% of the class. Each ADS represents 200 ordinary shares, and the filing bases the percentage on 6,085,450 common shares outstanding as of Sept 4, 2025. Lincoln reports sole voting and dispositive power over all 605,000 ADS and certifies the position was not acquired to change or influence control. The filing is signed by Stephen Temes as Managing Member on Sept 9, 2025. The issuer's principal office is listed in Rehovot, Israel.

Positive

• Transparent disclosure: Filing provides clear ownership amount and percentage based on an explicit share count.
• Sole voting/dispositive power: The filer states direct control over the reported shares, clarifying decision authority.
• Non-control certification: The filer declares the position was not acquired to change or influence control, consistent with passive 13G reporting.

Negative

• Large stake near 10%: The reported 9.94% position is close to common regulatory thresholds that draw investor and regulatory attention.
• Concentration risk: Ownership of 605,000 ADS represents a meaningful minority stake in a relatively small outstanding base of 6,085,450 shares.

Insights

Financial Analyst

TL;DR: A disclosed near-10% stake is material and may attract investor attention, but the filer asserts no intent to influence control.

Lincoln Alternative Strategies reports a 605,000 ADS position representing 9.94% of the ADS class. The filing confirms sole voting and dispositive power, indicating direct control of voting on these shares. The declaration that the securities were not acquired to influence control is standard for a Schedule 13G and suggests a passive intent. For investors, the key metric is the 9.94% ownership level relative to the outstanding base of 6,085,450 shares.

Corporate Governance Expert

TL;DR: This is a routine 13G disclosure showing substantial passive ownership with an explicit non-control certification.

The filing identifies Lincoln Alternative Strategies LLC as the reporting person with sole voting and dispositive power over all reported ADS. The signer, Stephen Temes as Managing Member, certifies the position is not intended to change or influence control, aligning with Schedule 13G treatment. The reported 9.94% stake is materially close to typical 10% reporting thresholds but remains below levels that would automatically imply control intent under the filer’s statement.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

PURPLE BIOTECH LTD.

(Name of Issuer)

American Depositary Shares, each representing 200 Ordinary Shares

(Title of Class of Securities)

74638P208

(CUSIP Number)

09/04/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 74638P208

1

Names of Reporting Persons

Lincoln Alternative Strategies LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 605,000.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 605,000.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

605,000.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.9 %

12

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person: Beneficial ownership percentage is based on 6,085,450 shares of the Issuer's common stock issued and outstanding as of September 4, 2025.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: PURPLE BIOTECH LTD.
(b)	Address of issuer's principal executive offices: 4 Oppenheimer Street, Science Park, Rehovot, ISRAEL, 7670104.
Item 2.
(a)	Name of person filing: Lincoln Alternative Strategies LLC
(b)	Address or principal business office or, if none, residence: 404 Washington Ave., Suite 650, Miami Beach, FL 33139
(c)	Citizenship: Delaware
(d)	Title of class of securities: American Depositary Shares, each representing 200 Ordinary Shares
(e)	CUSIP No.: 74638P208
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 605,000
(b)	Percent of class: 9.94%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 605,000
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 605,000
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Lincoln Alternative Strategies LLC

Signature:	/s/ Stephen Temes
Name/Title:	Stephen Temes/Managing Member
Date:	09/09/2025

FAQ

What stake in Purple Biotech (PPBT) did Lincoln Alternative Strategies report?

Lincoln reported beneficial ownership of 605,000 ADS, equal to 9.94% of the class.

How many ordinary shares does each ADS represent in this filing?

Each American Depositary Share represents 200 ordinary shares according to the filing.

Does Lincoln claim voting or dispositive power over the shares?

Yes. The filing states Lincoln has sole voting and sole dispositive power over all 605,000 ADS.

Was the position acquired to influence control of Purple Biotech?

No. The filing includes a certification that the securities were not acquired to change or influence control of the issuer.

On what outstanding share base is the 9.94% calculated?

The percentage is based on 6,085,450 shares outstanding as of Sept 4, 2025 per the filing.

Who signed the Schedule 13G for Lincoln Alternative Strategies?

The filing is signed by Stephen Temes, Managing Member, dated 09/09/2025.